Core Viewpoint - Genetron Holdings Limited is holding an extraordinary general meeting to vote on a proposed merger that would take the company private and terminate its listing on NASDAQ [1][2][3] Group 1: Merger Details - The merger involves Genetron Holdings Limited merging with New Genetron Holding Limited and Genetron New Co Limited, resulting in Genetron becoming a wholly-owned subsidiary of Parent [2] - If the merger is completed, Genetron's American depositary shares (ADSs) will no longer be traded on any stock exchange, and the ADS program will be terminated [2] - The board of directors has unanimously recommended that shareholders vote in favor of the merger agreement and related transactions [3] Group 2: Meeting Information - The extraordinary general meeting is scheduled for February 21, 2024, at 9:00 a.m. Beijing time, and shareholders of record as of February 9, 2024, will be entitled to vote [1][3] - ADS holders must instruct The Bank of New York Mellon to vote on their behalf by January 22, 2024 [3] Group 3: Company Overview - Genetron Holdings Limited is a leading precision oncology platform in China, specializing in molecular profiling tests, early cancer screening products, and companion diagnostics [1][6] - The company utilizes advanced technologies in molecular biology and data science to enhance cancer treatment and has developed a comprehensive oncology portfolio [6][7]
Genetron Health to Hold Extraordinary General Meeting of Shareholders